Body Pharm CJC-1295 + Ipamorelin 20mg

The Body Pharm 20mg pen pairs a DAC-modified GHRH analogue (CJC-1295) with a selective GHS-R1a agonist (Ipamorelin) in a single pre-filled research format, shipped from UK stock with batch-level traceability. CJC-1295 with DAC binds the GHRH receptor on somatotrophs to drive sustained GH release; the albumin conjugate extends plasma half-life to 6–8 days. Ipamorelin activates the ghrelin receptor (GHS-R1a) without measurable cortisol or prolactin elevation in published rodent work. Combining the two in one pen lets researchers model pulsatile GH dynamics without two separate reconstitutions, because the two compounds activate distinct signalling pathways that do not share a desensitisation mechanism. Component masses, HPLC purity figures and storage parameters are confirmed against the batch-specific Certificate of Analysis supplied with each unit, not assumed from category norms [1][2].

Key Takeaways

• CJC-1295 + Ipamorelin activates two distinct somatotroph receptors (GHRH-R and GHS-R1a) without overlapping desensitisation, producing synergistic GH release in published rodent and primate models
• The DAC moiety extends CJC-1295 half-life to 6–8 days; Ipamorelin provides selective GHS-R1a agonism without cortisol or prolactin spillover
• Pre-filled pen format eliminates reconstitution error and reduces sterility risk compared to lyophilised vials
• Every batch ships with a Certificate of Analysis linked to the batch number on the carton, enabling direct verification of purity and provenance
• UK dispatch removes customs delays and cold-chain exposure common to overseas orders

What Is CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin is a research peptide blend combining a DAC-modified GHRH analogue (CJC-1295) with a selective ghrelin-receptor agonist (Ipamorelin). The two compounds activate distinct somatotroph receptors (GHRH-R and GHS-R1a), producing additive GH release in published rodent and primate models without the cortisol or prolactin spillover seen with earlier GHRPs, because they couple to different intracellular signalling cascades.

CJC-1295 with DAC (Drug Affinity Complex) is a tetrasubstituted GHRH(1–29) analogue that covalently binds circulating albumin, extending its plasma half-life to roughly 6–8 days as characterised by Teichman et al. (2006, JCEM). Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) first described by Raun et al. (1998, Eur J Endocrinol) as a GHS-R1a agonist with GH-release potency comparable to GHRP-6 but without the ACTH, cortisol or prolactin elevation that limits other secretagogues.

Pairing them in one pen exploits non-overlapping desensitisation pathways: GHRH-R signals through Gαs/cAMP while GHS-R1a couples Gαq/PLC, so receptor downregulation on one axis does not blunt the other during repeat-dose research models. For dosing methodology after purchase, see the full CJC-1295 + Ipamorelin dosing protocol; for a head-to-head mechanistic breakdown, see CJC-1295 vs Ipamorelin: individual peptide comparison.

Mechanism: How the Blend Works at Receptor Level

The blend works because CJC-1295 and Ipamorelin activate two parallel somatotroph signalling cascades that converge on growth hormone exocytosis without sharing a desensitisation pathway. CJC-1295 binds the GHRH receptor (GHRH-R), a Gαs-coupled GPCR on anterior pituitary somatotrophs, raising intracellular cAMP and triggering PKA-mediated GH transcription and release. Ipamorelin binds GHS-R1a, a Gαq-coupled receptor, activating phospholipase C to generate IP3 and DAG, mobilising intracellular Ca²⁺ and amplifying the GH pulse independently of the cAMP arm.

Why DAC extends GHRH-R occupancy

The DAC moiety on CJC-1295 is a maleimidopropionic acid linker that forms a covalent thioether bond with Cys34 of circulating albumin. Albumin conjugation shields the peptide from DPP-IV cleavage and renal filtration. A single subcutaneous dose elevated serum IGF-1 for more than six days in healthy adults (Teichman et al., 2006). That sustained albumin tethering means GHRH-R remains accessible to ligand across multiple endogenous GH pulses, rather than only the post-injection window seen with native GHRH(1–29) or Mod-GRF(1–29).

Why Ipamorelin avoids cortisol and prolactin spillover

Ipamorelin is a selective GHS-R1a agonist that produced GH release comparable to GHRP-6 in rats without measurable elevation of ACTH, cortisol or prolactin at GH-releasing doses (Raun et al., 1998). That selectivity exists because Ipamorelin does not activate melanocortin-2 receptor (MC2R) or other off-target GPCRs that drive ACTH and prolactin release. It remains the preferred GHS pairing for a DAC-modified GHRH analogue in research models. Hexarelin and GHRP-2, by contrast, both raise cortisol in published rodent work.

The functional consequence in animal models is synergistic rather than additive GH output: GHRH-R priming increases the pool of releasable GH vesicles, and GHS-R1a co-stimulation then drives a larger amplitude pulse than either receptor produces alone. For the corresponding research-dosing methodology, see the full CJC-1295 + Ipamorelin dosing protocol.

Why a 20mg Combination Pen for Research?

A pre-filled 20mg combination pen removes two of the largest sources of variability in peptide research: reconstitution error and inter-dose sterility loss. The pen ships ready-to-dose, with CJC-1295 with DAC and Ipamorelin co-formulated in a single sealed cartridge. Each click delivers a fixed volume against a known total payload, rather than requiring the researcher to weigh, reconstitute with bacteriostatic water, and pipette from two separate lyophilised vials.

For comparative pharmacology, the molar pairing matters more than the mass pairing. Body Pharm formulates the 20mg blend so that GHRH-R and GHS-R1a are co-stimulated at functionally equivalent receptor occupancy in the model. The exact component breakdown is printed on the batch COA shipped with each pen rather than inferred from the label. Researchers running dose-response work should reference the COA molar values directly when calculating administered nmol/kg.

Format advantages over lyophilised vials

Lyophilised CJC-1295 and Ipamorelin vials require separate reconstitution, sequential injection or pre-mix in a third vial, and repeated septum penetration that accelerates microbial risk across a multi-week study. The sealed pen eliminates the bacteriostatic water step and reduces pipetting variance between doses. The cartridge preserves sterility across the dosing window because it remains sealed until the needle is inserted. For dose-volume conversions and frequency schedule, see the full CJC-1295 + Ipamorelin dosing protocol; for the mechanistic case for pairing rather than running the peptides in isolation, see CJC-1295 vs Ipamorelin: individual peptide comparison.

Body Pharm CJC-1295 + Ipamorelin 20mg: Product Specification

The Body Pharm 20mg blend ships as a sealed multi-dose subcutaneous pen with a per-batch Certificate of Analysis, free UK tracked Royal Mail delivery (1–3 working days), and 14-day returns on unused, unopened units. The specification below reflects current Body Pharm product data as of 2026. Component-level breakdown and exact HPLC purity are confirmed against the batch COA shipped inside each pack rather than inferred from the label.

For research and analytical purposes only. Not for human or veterinary use, not for diagnostic procedures, not for food or cosmetic formulation. Researchers progressing to dose calculation should cross-reference the COA molar values against the full CJC-1295 + Ipamorelin dosing protocol.

Quality, Sourcing & Batch Traceability

Every Body Pharm CJC-1295 + Ipamorelin pen is filled, sealed, and dose-validated in the UK before dispatch, with a batch number printed on the outer pack that maps directly to a per-batch Certificate of Analysis. That batch number is the single reference a research team uses to verify identity, purity and provenance against the COA shipped inside the pack. Analytical confirmation relies on HPLC at minimum, with mass spectrometry applied where peptide identity needs orthogonal confirmation. The exact purity threshold and method readout are stated on the batch sheet rather than generalised across stock.

Full traceability means three concrete things: the COA references the same batch number on the carton, the synthesis date is recorded, and the analytical results are tied to that specific fill rather than a generic product specification. Grey-market suppliers routinely ship without a COA, or attach a generic one unlinked to the unit in hand, which leaves no way to audit what was actually injected into the research model. Researchers concerned about supply chain integrity should verify the batch number against the published COA before use.

Dispatching from within the UK removes two failure modes common to overseas orders: customs holds that stretch transit beyond cold-chain tolerance, and unverifiable temperature exposure in third-country freight. For researchers planning a study window, that matters more than headline price, because cold-chain breaks can degrade peptide potency before the pen reaches the laboratory. The next procedural step is cross-referencing the COA molar values against the full CJC-1295 + Ipamorelin dosing protocol, or reviewing the CJC-1295 vs Ipamorelin: individual peptide comparison before finalising the combination rationale.

Dosing Protocols for CJC-1295 + Ipamorelin Research

Preclinical dosing for the CJC-1295 + Ipamorelin combination depends on the specific research model, route, and endpoint; no human dose is implied or provided here. The product is supplied pre-filled for subcutaneous administration in research models — there is no reconstitution step. Full titration mechanics and injection-frequency variables (the protocol runs a single evening dose per day) are documented in the full CJC-1295 + Ipamorelin dosing protocol rather than summarised on this page.

One variable worth flagging at the protocol-design stage is administration timing relative to endogenous GH pulsatility. Giustina and Veldhuis (Endocrine Reviews, 1998) characterised the nocturnal GH pulse architecture that later secretagogue work used as a reference point. Many in vivo protocols specify pre-sleep-phase dosing windows in rodent models. Whether a given study design benefits from synchronising with that pulse, or deliberately offsetting it, depends on the readout being measured, because the timing affects whether the exogenous GH signal amplifies or dampens the endogenous pulse.

Researchers still weighing the combination rationale itself, rather than the dosing arithmetic, should review the CJC-1295 vs Ipamorelin: individual peptide comparison before finalising a protocol.

CJC-1295 vs Ipamorelin: Individual vs Combined Use

The combination engages two distinct receptor pathways simultaneously, which is why most post-2010 rodent secretagogue work uses the pairing rather than either peptide alone. CJC-1295 with DAC binds GHRH-R on somatotrophs and provides sustained GHRH-axis stimulation across days, but it depends on endogenous ghrelin tone for GHS-R1a input. Ipamorelin supplies that GHS-R1a agonism selectively, without measurable effect on cortisol or prolactin in the original Raun et al. characterisation, but its plasma half-life is short (approximately 2 hours).

Pairing them allows the GHRH-R signal to remain elevated while the GHS-R1a pulse is delivered on the researcher's schedule rather than on the model's circadian ghrelin rhythm. Published rodent work reports synergy in the combination, though no peer-reviewed in vivo study isolating the specific Body Pharm pen formulation against its components has been published to date. Researchers comparing the combination against single-agent protocols should consult the full mechanistic comparison before protocol finalisation.

The full mechanistic argument, including receptor kinetics and pulse-amplitude data, sits in the CJC-1295 vs Ipamorelin individual peptide comparison.

Ordering, Delivery & Returns: UK Research Buyers

All orders ship free within the UK via Royal Mail tracked, in plain unbranded outer packaging, with typical delivery in 1–3 working days. Body Pharm dispatches from a UK facility, so there are no import duties, no customs holds, and no cross-border handovers between carriers.

Unused, unopened items can be returned within 14 days of receipt for a refund. Used or opened pens cannot be returned, for sterility and chain-of-custody reasons consistent with research-chemical handling. Tracking numbers are issued at dispatch and visible in your account.

If the 20mg blend pen shows as out of stock, use the notify-me option on the product page to register interest. You will receive a single email when the next QC-released batch is available, with the batch reference included so procurement can cross-check against the published COA before re-ordering.

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC (Drug Affinity Complex) carries a maleimide linker that binds covalently to serum albumin, extending plasma half-life to approximately 6–8 days and producing a sustained GHRH-receptor signal. CJC-1295 without DAC (also called Mod GRF 1-29) lacks the linker and clears within approximately 30 minutes, producing a sharper, pulse-aligned signal. The Body Pharm 20mg pen uses the DAC-modified analogue to maintain steady GHRH tone between Ipamorelin-driven GHS-R1a pulses.

Is CJC-1295 + Ipamorelin legal to buy in the UK for research?

CJC-1295 and Ipamorelin are not listed under the Misuse of Drugs Act 1971 and are supplied in the UK as research chemicals for in vitro and non-human laboratory use only. They are not licensed by the MHRA for human administration. Buyers should verify current MHRA and Home Office status at the point of purchase and ensure institutional approval for their intended research use.

How should the pen be stored?

Store the sealed pen at 2–8 °C, protected from light. Unopened shelf life is 24 months; once first used (pierced), keep refrigerated and use within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. Never freeze the pen, and discard any pen showing cloudiness or particulate matter.

What purity standard does Body Pharm use?

Body Pharm releases each batch at ≥98% HPLC purity, with mass confirmation by LC-MS and endotoxin screening. The batch-specific COA is published against the lot number printed on the pen, so procurement can cross-check before accepting delivery.

Can I buy CJC-1295 + Ipamorelin with free UK delivery?

Yes. All UK orders ship free via Royal Mail tracked, dispatched from a UK facility with no customs handling.

Next Steps

Add the pen to your basket above, or read the full CJC-1295 + Ipamorelin dosing protocol before you order. If you are still comparing the combination against single-agent use, consult the CJC-1295 vs Ipamorelin: individual peptide comparison to finalise your protocol rationale.

References

1. Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov/16352683
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov/9849822